IGC Pharma IGC 深 沪
已收盘 08-21 16:00:00 美东时间
0.308
+0.031
+11.11%
华盛通- 最 高0.31
- 今 开0.2875
- 成交量 186.74万股
- 最 低 0.2787
- 昨 收 0.2772
- 总市值 3184.23万
- 52周最高 0.47
- 市盈率 静 --
- 换手率 1.81%
- 52周最低 0.235
- 委 比 -42.86%
- 总股本 1.03亿
- 历史最高 14.58
- 量 比 1.95
- 振 幅 11.29%
- 历史最低 0.235
- 每 手 1
- 风险率 0.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $265.000 thousand which be...
08-17 20:40
IGC Pharma Says CEO Ram Mukunda And Principal Financial Officer Claudia Grimaldi Purchase Aggregate Of 4,274,853 Shares Directly From Company At $0.27/Shr
Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage bio...
07-07 21:03
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.5
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.25 to $5.5.
06-08 17:21
"Marijuana Components Have 'Consistent' Anti-Tumor Effects In Glioblastoma And Other Cancers, Scientific Review Shows" - Marijuana Moment
https://www.marijuanamoment.net/marijuana-components-have-consistent-anti-tumor-effec
05-29 23:13
IGC Pharma Receives Authorization In Colombia To Synthesize, Formulate, And Conduct Development Activities Involving Psilocybin At Its R&D Facility In Bogotá
Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completionPOTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc. (NYSE:IGC)
04-20 20:33
美股大行评级 | 瑞银上调美光科技目标价从510升至535美元；巴克莱下调Robinhood 目标价从124降至89美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5美元升至5.25美元；Benchmark：维持Direct Digital Holdings"投机性买入"评级，目标价从2美元升至8美元
04-09 10:15
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.25
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5 to $5.25.
04-08 17:56
'Medicare CBD Pilot Will Allow Some THC in Products'- Cannabis Wire
https://cannabiswire.com/newsletters/scoop-medicare-cbd-pilot-will-allow-some-thc-in-products/?free_read=1773920530418
03-19 22:30
IGC Pharma Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $213.000K Miss $325.000K Estimate
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period
03-19 21:25
